Literature DB >> 18021218

Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB-IIA cervical cancer.

K-B Lee1, J-M Lee, K-D Ki, S-K Lee, C-Y Park, S-Y Ha.   

Abstract

The aim of this study was to compare the outcome of chemotherapy or radiation as adjuvant therapy for patients with FIGO stage IB-IIA cervical cancer and surgically confirmed intermediate risk factors. Data were collected from patients with uterine cervical cancer FIGO stage IB-IIA who had adjuvant chemotherapy following radical hysterectomy with pelvic lymph node dissection (RHLND, cases) or adjuvant radiotherapy following RHLND (controls). The study groups consisted of 38 cases and 42 controls. Adjuvant treatment was given to the patients with a combination of intermediate risk factors including deep stromal invasion (>50%), lymphvascular space invasion, large tumor size (3-6 cm), or close vaginal resection margin (<1 cm). Comparison of the cases with the controls revealed no significant differences in variables studied including median age (P = 0.18), stage distribution (P = 0.30), histologic subtype (P = 0.93), pathologic tumor size (P = 0.46), depth of the stromal invasion (P = 0.29), lymphvascular space invasion (P = 0.50), and close vaginal resection margin (P = 0.62). The difference in disease-free survival rates was not significant (P = 0.68). However, the overall survival analysis was incomplete due to the limited number of events available at the end of the study period. The findings of this study suggest that adjuvant chemotherapy in patients with FIGO stage IB-IIA uterine cervical cancer and surgically confirmed intermediate risk factors may be effective.

Entities:  

Mesh:

Year:  2007        PMID: 18021218     DOI: 10.1111/j.1525-1438.2007.01136.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  Optimal MRI interval for detection of asymptomatic recurrence in surgically treated early cervical cancer by use of a mathematical model.

Authors:  A Laios; K Gubbala; R Lampe; A Tolis
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

2.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

3.  Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients.

Authors:  Yun Liang; Bingjian Lü; Xiaoduan Chen; Jiale Qin; Xiaodong Cheng; Xing Xie; Weiguo Lü
Journal:  Virchows Arch       Date:  2015-12-04       Impact factor: 4.064

4.  Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.

Authors:  Phill-Seung Jung; Dae-Yeon Kim; Shin-Wha Lee; Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

5.  NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer.

Authors:  Chunhao Niu; Xiaoying Sun; Weijing Zhang; Han Li; Liqun Xu; Jun Li; Benke Xu; Yanna Zhang
Journal:  Int J Mol Sci       Date:  2016-10-20       Impact factor: 5.923

6.  Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).

Authors:  Kazuto Nakamura; Yoshikazu Kitahara; Toyomi Satoh; Yuji Takei; Masashi Takano; Shoji Nagao; Isao Sekiguchi; Mitsuaki Suzuki
Journal:  World J Surg Oncol       Date:  2016-06-29       Impact factor: 2.754

7.  Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.

Authors:  Koji Matsuo; Muneaki Shimada; Harushige Yokota; Toyomi Satoh; Hidetaka Katabuchi; Shoji Kodama; Hiroshi Sasaki; Noriomi Matsumura; Mikio Mikami; Toru Sugiyama
Journal:  Oncotarget       Date:  2017-11-15

8.  Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB-IIA cervical cancer patients.

Authors:  Kwang Beom Lee; Young Saing Kim; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

9.  Adjuvant chemotherapy for early-stage cervical cancer.

Authors:  Hiroshi Asano; Yukiharu Todo; Hidemichi Watari
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

10.  Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study.

Authors:  Lei Li; XiaoYan Song; RuoNan Liu; Nan Li; Ye Zhang; Yan Cheng; HongTu Chao; LiYing Wang
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.